慢性乙型病毒性肝炎患者检测肽抗菌药物Cathelicidin hCAP18/LL-37的临床意义

目的 探讨肽抗菌药物hCAP18/LL-37在慢性乙型病毒性肝炎(乙型肝炎)中的临床意义.方法 将90例慢性乙型肝炎患者分成轻、中、重3组,每组30例,用微孔法酶联免疫吸附实验分别检测患者血浆LL-37水平,并与健康对照组(n=30)比较,同时进行组间比较.结果 慢性乙型肝炎患者血浆的LL-37水平显著低于健康对照组(P<0.01).患者血浆中LL-37水平在慢性乙型肝炎轻、中、重组中均值分别是38.93、33.11、12.87 ng/mL,随病情加重而逐渐降低,组间比较差异有统计学意义(P<0.01).结论 LL-37检测可作为慢性乙型肝炎患者临床判断病情和预后的一个标志物.

Clinical value of detecting plasma cathelicidin hCAP18/LL-37 in patients with chronic hepatitis B

Objective To analyze serocym LL-37 levels in hepatitis B virus-infected subjects,and to explore the correlation with plasma LL-37 levels and liver damage in HBV-infected subjects.Methods Plasma samples were obtained from 90 hepatitis B virus-infected subjects,these subjects were divided three groups as hepatitis B virus patients with mild,moderate and severe chronic B hepatitis.Plasma LL-37 levels were determined using enzyme-linked immunosorbent assay.Results The mean plasma LL-37 concentrations in HBV mild,moderate and severe chronic B virus were lower than matched healthy controls(P<0.01).Plasma LL-37 levels decreased with liver damage(P<0.01).They were 38.93,33.11,12.87 ng/mL.Conclusion Plasma LL-37 levels provides a useful marker of define disease progression of HBV infection.The change of plasma LL-37 level in patients with chronic hepatitis B can assist diagnosis and predicting prognosis.